携尿激酶靶向微泡造影剂的体外溶栓实验研究  

Thrombolysis of Targeted Microbubbles Carrying Urokinase in Vitro

作　　者：李玲[1] 穆玉明[1] 关丽娜[1] 郭朝峰[1] 

机构地区：[1]新疆医科大学第一附属医院超声医学中心心脏超声诊断科,乌鲁木齐市830054

出　　处：《中国超声医学杂志》2009年第7期628-631,共4页Chinese Journal of Ultrasound in Medicine

基　　金：国家自然科学基金（No.30860267）

摘　　要：目的制备携尿激酶及精氨酸甘氨酸天冬氨酸丝氨酸（RGDS）的靶向溶栓造影剂，并研究其对体外血栓的溶解作用。 方法通过直接连接法将尿激酶、RGDS连接到造影剂声诺维上。制备血块，分为4组，分别注入生理盐水、声诺维、尿激酶及所制备的造影剂，计算处理前后的血块质量差，算出溶栓率，进行统计学分析。 结果荧光显微镜及流式细胞仪检测结果均显示，声诺维成功携带了尿激酶及RGDS，携带率分别为（72．3±9．4）％、（64．6±10．2）％。加入所制备的携药造影剂组溶栓前后血块质量改变显著，差异具有统计学意义，血栓溶解率（18．4±3．2）％。 结论携尿激酶及RGDS的靶向溶栓造影剂成功制备。所制备的造影剂在体外具有血栓溶解作用。Objective Preparation of a thrombus-targeted ultrasound contrast agent carrying Urokinase （UK） and Arg-Gly-Asp Ser （RGDS） and the assessment of its thrombolysis ability in vitro. Methods Urokinase and RGDS were combined to the surface of SonoVue by using a direct connection method. Then prepare blood clots. These clots were divided into four groups randomly. The clots were treated with NaCl, SonoVue, UK, and the prepared contrast agent. The clot mass loss after treatment and thrombolytic rate were calculated. The results were analyzed by statistics. Results The results of fluorescence microscope and flow cytornetry test showed that urokinase and RGDS were conjuncted successfulIy to SonoVue and the binding rates of urokinase and RGDS were （ 72.3 ± 9.4 ） %, （ 64.6 ±10.2）%. The clot mass loss of,injecting prepared contrast agent was significant. Its rate of thrombolysis was （18.4±3.2） %. Conclusions The thrombus-targeted ultrasound contrast agent carrying urokinase and RGDS was prepared successfully and it had thrombolysis ability in vitro.

关 键 词：靶向微泡造影剂 尿激酶 体外溶栓 

分 类 号：R543[医药卫生—心血管疾病] R973.2[医药卫生—内科学]